Skip to main content
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. — Investor Relations & Filings

Ticker · TRDA ISIN · US29384C1080 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2025-04-25 Proxy Solicitation & In…
Country US United States of America
Listing US TRDA

About Entrada Therapeutics, Inc.

https://www.entradatx.com/

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of medicines to treat devastating diseases. The company's proprietary Endosomal Escape Vehicle (EEV) platform is designed to enable the intracellular delivery of a wide range of therapeutics, allowing access to targets that have historically been considered undruggable. Entrada's development pipeline is concentrated on rare conditions, with programs targeting neuromuscular diseases, including Duchenne muscular dystrophy, as well as ocular diseases. The company's mission is to transform the lives of patients by establishing EEV-based therapeutics as a new treatment modality.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about voting on director elections and ratification of the auditor, typical content for proxy solicitation materials. The text explicitly mentions it is a 'Definitive Additional Materials' filing related to the 2025 Annual Meeting and provides voting instructions and proposals. It is not the actual Annual Report, nor an announcement of voting results, but materials sent to shareholders to provide information and request votes for the meeting. Therefore, the document fits the Proxy Solicitation & Information Statement category (PSI). The document length is under 5,000 characters, but it contains substantive proxy solicitation content, not just a brief announcement, so it is not an RPA or RNS filing.
2025-04-25 English
FORM DEF 14A
Proxy Solicitation & Information Statement
2025-04-25 English
FORM 4
Director's Dealing
2025-04-04 English
FORM S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by Entrada Therapeutics, Inc. It registers shares of common stock under an inducement equity plan. The text includes detailed information about the plan, incorporation by reference of other SEC filings, indemnification provisions, and undertakings related to the registration statement. Form S-8 is a specific SEC filing used to register securities to be offered to employees under employee benefit plans. This is not an annual report, earnings release, or any other financial report type. It is a capital market filing related to securities registration and employee equity plans. According to the provided filing definitions, none exactly match Form S-8, but the closest and most appropriate category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories. The document is substantive and not a mere announcement, so it is not Report Publication Announcement (RPA). Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2025-03-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Entrada Therapeutics, Inc. It reports a recent event dated March 24, 2025, specifically the authorization to initiate a Phase 1/2 clinical study in the UK. The content includes a press release about this regulatory and clinical trial update. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a material event (clinical trial authorization) and includes forward-looking statements. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like earnings release, annual report, or capital update. The document length (8267 characters) and content confirm it is not a brief report publication announcement or a certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-03-24 English
FORM 4
Director's Dealing
2025-03-19 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.